Please Wait
Applying Filters...
menu
    • menu
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Olmesartan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 823Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 144689-63-4, Benicar, Olmetec, Cs-866, Cs 866, Nsc-758924
    Molecular Formula
    C29H30N6O6
    Molecular Weight
    558.6  g/mol
    InChI Key
    UQGKUQLKSCSZGY-UHFFFAOYSA-N
    FDA UNII
    6M97XTV3HD
    An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
    2.1.2 InChI
    InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)
    2.1.3 InChI Key
    UQGKUQLKSCSZGY-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O
    2.2 Other Identifiers
    2.2.1 UNII
    6M97XTV3HD
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate - T287346

    2. Benicar

    3. Cs 866

    4. Cs-866

    5. Cs866

    6. Medoxomil, Olmesartan

    7. Olmetec

    8. Votum

    2.3.2 Depositor-Supplied Synonyms

    1. 144689-63-4

    2. Benicar

    3. Olmetec

    4. Cs-866

    5. Cs 866

    6. Nsc-758924

    7. 6m97xtv3hd

    8. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

    9. 1h-imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

    10. Ncgc00095136-01

    11. Benevas

    12. Olsertain

    13. Olvance

    14. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

    15. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

    16. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

    17. Benicar (tn)

    18. Olmetec (tn)

    19. Cs866

    20. Sr-05000001987

    21. Unii-6m97xtv3hd

    22. Votume

    23. Openvas

    24. Cs-866dm

    25. Cs-866rn

    26. Olmesartanmedoxomil

    27. Olmesartan-medoxomil

    28. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

    29. Olmesartan Medoxomil [usan:inn:ban]

    30. Ks-1182

    31. Olmesartan (medoxomil)

    32. Spectrum_001944

    33. Spectrum2_000506

    34. Spectrum3_001676

    35. Spectrum4_000740

    36. Spectrum5_001556

    37. Dsstox_cid_25924

    38. Dsstox_rid_81226

    39. Dsstox_gsid_45924

    40. Schembl16403

    41. Bspbio_003491

    42. Gtpl591

    43. Kbiogr_001040

    44. Kbioss_002498

    45. 1h-imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) Methyl Ester

    46. Mls006010109

    47. Spectrum1505205

    48. Spbio_000431

    49. Olmesartan Medoxomil (benicar)

    50. Chembl1200692

    51. Dtxsid9045924

    52. Chebi:31932

    53. Kbio2_002490

    54. Kbio2_005058

    55. Kbio2_007626

    56. Kbio3_002711

    57. Hms1922l15

    58. Hms2089k18

    59. Hms2093k16

    60. Hms3651e13

    61. Hms3715n09

    62. Hms3743o09

    63. Olmesartan Medoxomil (jp17/usp)

    64. Olmesartan Medoxomil [inn]

    65. Olmesartan Medoxomil [jan]

    66. Pharmakon1600-01505205

    67. Olmesartan Medoxomil [usan]

    68. Amy22222

    69. Bcp05214

    70. Zinc4149248

    71. Olmesartan Medoxomil [vandf]

    72. Tox21_111445

    73. Bdbm50442892

    74. Ccg-39596

    75. Mfcd00944911

    76. Nsc758924

    77. Olmesartan Medoxomil [mart.]

    78. S1604

    79. Stl451024

    80. Olmesartan Medoxomil [usp-rs]

    81. Olmesartan Medoxomil [who-dd]

    82. Akos015894907

    83. Akos015914772

    84. Ac-1601

    85. Bcp9000555

    86. Ccg-221184

    87. Cs-0577

    88. Nsc 758924

    89. Olmesartan Medoxomil, >=98% (hplc)

    90. Sb19327

    91. Ncgc00095136-02

    92. Ncgc00095136-03

    93. Ncgc00095136-09

    94. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

    95. Azor Component Olmesartan Medoxomil

    96. Hy-17005

    97. Olmesartan Medoxomil [orange Book]

    98. Smr002203616

    99. Olmesartan Medoxomil [ep Monograph]

    100. Sbi-0206741.p001

    101. Olmesartan Medoxomil [usp Monograph]

    102. Cas-144689-63-4

    103. Ft-0601603

    104. O0510

    105. Olmesartan Medoxomil Component Of Azor

    106. Sw199650-2

    107. D01204

    108. Tribenzor Component Olmesartan Medoxomil

    109. Ab01275443-01

    110. Ab01275443_02

    111. Ab01275443_03

    112. Benicar Hct Component Olmesartan Medoxomil

    113. 689o634

    114. A808260

    115. L001061

    116. Olmesartan Medoxomil Component Of Tribenzor

    117. J-501595

    118. Olmesartan Medoxomil Component Of Benicar Hct

    119. Sr-05000001987-1

    120. Sr-05000001987-2

    121. Brd-k78485176-001-02-9

    122. Brd-k78485176-001-03-7

    123. Q27888058

    124. Z1550675457

    125. Olmesartan Medoxomil, European Pharmacopoeia (ep) Reference Standard

    126. Olmesartan Medoxomil, United States Pharmacopeia (usp) Reference Standard

    127. Olmesartan Medoxomil For System Suitability, European Pharmacopoeia (ep) Reference Standard

    128. Olmesartan Medoxomil, Pharmaceutical Secondary Standard; Certified Reference Material

    129. (5-methyl-2-oxidanylidene-1,3-dioxol-4-yl)methyl 5-(2-oxidanylpropan-2-yl)-2-propyl-3-[[4-[2-(2h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

    130. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-i Midazole-5-carboxylate

    131. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

    132. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-[[2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-4-(2-hydroxypr

    133. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxy-2-propanyl)-2-propyl-1-[[2'-(1h-tetrazol-5-yl)-4-biphenylyl]methyl]-1h-imidazole-5-carboxylate

    134. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylate

    135. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

    136. (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylate

    137. (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate

    138. (5-methyl-2-oxo-1,3-dioxolen-4yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate

    139. (5-methyl-2-oxo-2h-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1h-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1h-imidazole-5-carboxylate

    140. 1h-imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3- Dioxol-4-yl)methyl Ester

    141. 1h-imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

    142. 5-(1-hydroxy-1-methylethyl)-2-propyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazole-4-carboxylic Acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl Ester

    143. 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolecarboxylic Acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

    144. Olmesartan Medoxomil

    145. 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylic Acid-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 558.6 g/mol
    Molecular Formula C29H30N6O6
    XLogP33.8
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count10
    Rotatable Bond Count11
    Exact Mass558.22268270 g/mol
    Monoisotopic Mass558.22268270 g/mol
    Topological Polar Surface Area154 Ų
    Heavy Atom Count41
    Formal Charge0
    Complexity969
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 6  
    Drug NameBenicar
    Drug LabelBENICAR (olmesartan medoxomil), a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist.Olmesartan medoxomil is described chemically as 2,3-d...
    Active IngredientOlmesartan medoxomil
    Dosage FormTablet
    RouteOral
    Strength5mg; 40mg; 20mg
    Market StatusPrescription
    CompanyDaiichi Sankyo

    2 of 6  
    Drug NameBenicar hct
    PubMed HealthOlmesartan (By mouth)
    Drug ClassesCardiovascular Agent, Renal Protective Agent
    Active Ingredientolmesartan medoxomil; Hydrochlorothiazide
    Dosage FormTablet
    RouteOral
    Strength25mg; 12.5mg; 40mg; 20mg
    Market StatusPrescription
    CompanyDaiichi Sankyo

    3 of 6  
    Drug NameOlmesartan medoxomil
    PubMed HealthOlmesartan/Hydrochlorothiazide (By mouth)
    Drug ClassesAngiotensin II Receptor Antagonist/Thiazide Combination
    Drug LabelBENICAR (olmesartan medoxomil), a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist.Olmesartan medoxomil is described chemically as 2,3-d...
    Active IngredientOlmesartan medoxomil
    Dosage FormTablet
    Routeoral
    Strength5mg; 40mg; 20mg
    Market StatusTentative Approval
    CompanyMylan Pharma; Sandoz

    4 of 6  
    Drug NameBenicar
    Drug LabelBENICAR (olmesartan medoxomil), a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist.Olmesartan medoxomil is described chemically as 2,3-d...
    Active IngredientOlmesartan medoxomil
    Dosage FormTablet
    RouteOral
    Strength5mg; 40mg; 20mg
    Market StatusPrescription
    CompanyDaiichi Sankyo

    5 of 6  
    Drug NameBenicar hct
    PubMed HealthOlmesartan (By mouth)
    Drug ClassesCardiovascular Agent, Renal Protective Agent
    Active Ingredientolmesartan medoxomil; Hydrochlorothiazide
    Dosage FormTablet
    RouteOral
    Strength25mg; 12.5mg; 40mg; 20mg
    Market StatusPrescription
    CompanyDaiichi Sankyo

    6 of 6  
    Drug NameOlmesartan medoxomil
    PubMed HealthOlmesartan/Hydrochlorothiazide (By mouth)
    Drug ClassesAngiotensin II Receptor Antagonist/Thiazide Combination
    Drug LabelBENICAR (olmesartan medoxomil), a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist.Olmesartan medoxomil is described chemically as 2,3-d...
    Active IngredientOlmesartan medoxomil
    Dosage FormTablet
    Routeoral
    Strength5mg; 40mg; 20mg
    Market StatusTentative Approval
    CompanyMylan Pharma; Sandoz

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Antihypertensive Agents

    Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)

    Angiotensin II Type 1 Receptor Blockers

    Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. (See all compounds classified as Angiotensin II Type 1 Receptor Blockers.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    Angiotensin 2 Receptor Blocker [EPC]; Angiotensin 2 Receptor Antagonists [MoA]
    5.3 ATC Code

    C09CA08

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    C - Cardiovascular system

    C09 - Agents acting on the renin-angiotensin system

    C09C - Angiotensin ii receptor blockers (arbs), plain

    C09CA - Angiotensin ii receptor blockers (arbs), plain

    C09CA08 - Olmesartan medoxomil